Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Stroke Cerebrovasc Dis ; 33(1): 107432, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37966093

RESUMO

OBJECTIVES: Medical tourism is expanding globally, with patients seeking cosmetic procedures abroad. To date, little information is known regarding the risks and outcomes of cosmetic tourism, especially potential stroke complications. Here, we present a case of fungal meningitis in the setting of medical tourism leading to ischemic strokes and vasospasm. MATERIAL AND METHODS: We describe an immunocompetent 29-year-old female patient who initially presented with intractable headaches and an abnormal cerebrospinal fluid (CSF) profile who was eventually diagnosed with Fusarium solani meningitis as a part of a common source outbreak in Matamoros, Mexico. These patients were part of a cohort who underwent cosmetic procedures requiring spinal anesthesia. This report also highlights the unusual clinical course leading to poor outcomes in such conditions. RESULTS: The patient initially presented with headaches, papilledema, elevated opening pressure on the spinal tap, abnormal CSF studies, and eventually developed ischemic strokes and hydrocephalus. CSF showed positive beta D-Glucan with repeated negative CSF fungal cultures. A cerebral angiogram revealed extensive basilar artery vasospasm that led to ischemic strokes. Continued clinical worsening and lack of response to antifungal treatment prompted further imaging that revealed significant non-obstructive hydrocephalus subsequently complicated by spontaneous intracranial hemorrhage. CSF PCR for Fusarium solani species was positive days after her passing. CONCLUSION: This novel case highlights fungal meningitis caused by Fusarium solani complicated by bilateral ischemic strokes stemming from basilar artery vasospasm. Complications from medical tourism impact not only individual patients but also the health systems of both countries. Professional and regulatory entities for cosmetic surgeries must highlight and educate patients on the risks and complications of cosmetic surgeries happening abroad. Physicians should be aware of ongoing outbreaks and possible complications of these procedures.


Assuntos
Hidrocefalia , AVC Isquêmico , Turismo Médico , Meningite Fúngica , Meningite , Vasoespasmo Intracraniano , Humanos , Feminino , Adulto , Vasoespasmo Intracraniano/complicações , Vasoespasmo Intracraniano/diagnóstico por imagem , Meningite Fúngica/complicações , Meningite Fúngica/diagnóstico , Meningite Fúngica/tratamento farmacológico , Hidrocefalia/cirurgia
2.
Int J Neurosci ; : 1-5, 2023 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-37942652

RESUMO

INTRODUCTION: Parry Romberg Syndrome (PRS) is a less common genetic condition presenting with progressive hemifacial atrophy involving skin, underlying connective tissue, muscle and facial bone. Neurological manifestations include seizures, headaches, deafness and trigeminal neuralgia refractory to medications, while stroke is a less common presentation. MATERIALS AND METHODS: A 43-year-old right-handed female with previous history of Lower Motor Neuron (LMN) type facial palsy, seizure disorder and linear scleroderma, presented to our clinic with recurrent cryptogenic strokes. She developed progressive hemifacial atrophy on the left side and left eye ectropion and was eventually diagnosed with rare Parry Romberg Syndrome. RESULTS: Patient underwent extensive work up for stroke to rule out etiologies like hyperlipidemia, diabetes, lupus and vasculitis. Peripheral labs for inflammatory markers and Cerebrospinal fluid (CSF) studies were unremarkable. Brain imaging at different points in time showed progressive atrophy of brain parenchyma, overlying bone, connective tissue and facial muscles on the left side. Central Nervous System (CNS) vessel imaging and diagnostic cerebral angiogram was unremarkable. CONCLUSION: This novel case underscores the potential CNS involvement in PRS, which is a rare disease entity. Neurological manifestations are not uncommon, including stroke. Further research is needed to understand the mechanisms of stroke in this rare disease process, that could help develop potential therapeutic targets.

3.
J Alzheimers Dis ; 96(3): 1267-1283, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37955086

RESUMO

BACKGROUND: Neuroimaging bears the promise of providing new biomarkers that could refine the diagnosis of dementia. Still, obtaining the pathology data required to validate the relationship between neuroimaging markers and neurological changes is challenging. Existing data repositories are focused on a single pathology, are too small, or do not precisely match neuroimaging and pathology findings. OBJECTIVE: The new data repository introduced in this work, the South Texas Alzheimer's Disease research center repository, was designed to address these limitations. Our repository covers a broad diversity of dementias, spans a wide age range, and was specifically designed to draw exact correspondences between neuroimaging and pathology data. METHODS: Using four different MRI sequences, we are reaching a sample size that allows for validating multimodal neuroimaging biomarkers and studying comorbid conditions. Our imaging protocol was designed to capture markers of cerebrovascular disease and related lesions. Quantification of these lesions is currently underway with MRI-guided histopathological examination. RESULTS: A total of 139 postmortem brains (70 females) with mean age of 77.9 years were collected, with 71 brains fully analyzed. Of these, only 3% showed evidence of AD-only pathology and 76% had high prevalence of multiple pathologies contributing to clinical diagnosis. CONCLUSION: This repository has a significant (and increasing) sample size consisting of a wide range of neurodegenerative disorders and employs advanced imaging protocols and MRI-guided histopathological analysis to help disentangle the effects of comorbid disorders to refine diagnosis, prognosis and better understand neurodegenerative disorders.


Assuntos
Doença de Alzheimer , Doenças Neurodegenerativas , Feminino , Humanos , Idoso , Doença de Alzheimer/patologia , Texas/epidemiologia , Encéfalo/diagnóstico por imagem , Encéfalo/patologia , Neuroimagem/métodos , Imageamento por Ressonância Magnética , Doenças Neurodegenerativas/patologia , Biomarcadores
4.
Cureus ; 13(10): e18698, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34790456

RESUMO

BACKGROUND: Vagus nerve stimulation (VNS) functions through neuromodulatory mechanisms to provide quality of life improvements to those with drug-resistant epilepsy. Responsive VNS (rVNS) generators are designed to further reduce seizure burden by detecting ictal tachycardia and aborting seizures soon after their onset.  Methods: Electronic medical records were accessed from January 2015 to December 2018 to identify patients with epilepsy managed with rVNS generators. Data were collected on seizure burden before and after rVNS implantation. Seizure burden was compared using t-tests, and monthly seizure reductions were gauged with the McHugh scale. Twenty-seven individuals met inclusion criteria; 10 were eliminated due to prior VNS implantation or undocumented seizure frequencies. RESULTS: The average seizure burden prior to rVNS implantation was 24.78 seizures/month. Following generator placement, the mean seizure frequencies at three months, six months, 12 months, and 18 months were 6.81, 16.57, 5.65, and 5.78 seizures/month, respectively. However, despite documented reductions in the average monthly seizure frequency, we found no statistically significant differences in seizure frequency relative to baseline. CONCLUSION: While many participants showed individual reductions in seizure burden, this study was unable to definitively conclude that rVNS therapy leads to statistically significant reduction in seizure burden.

5.
Asian J Psychiatr ; 55: 102501, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33296864

RESUMO

AIM: This study aimed to assess the relationship between neurocognition (NC) and social cognition (SC) in patients with schizophrenia during the symptomatic phase and the phase of clinical remission. METHODOLOGY: Thirty-two patients were assessed on Color trail test (CTT), Hopkins verbal learning test (HVLT), Controlled oral word association (COWA) test, Wisconsin card sorting test (WCST), Ravens standard progressive matrices (SPM) and Social cognition rating tool in Indian setting (SOCRATIS) during symptomatic and remission phases of illness at least 3 months apart. RESULTS: Compared to baseline assessment, even after controlling for PANSS scores except for social perception index all other domains of SC showed significant improvement at the time of remission. Although there was significant improvement in a few subtests of verbal learning, IQ and number of correct responses of COWA, colour trail test, no significant difference was seen in performance on WCST. Although second order theory of mind task had some association with IQ at the baseline assessment, no association was seen between SC and NC in the remission phase. CONCLUSIONS: To conclude, present study suggests that impairments in all the domains of SC (except for social perception index) and NC (except for WCST) improve in the remission phase.


Assuntos
Transtornos Cognitivos , Disfunção Cognitiva , Esquizofrenia , Cognição , Disfunção Cognitiva/etiologia , Humanos , Testes Neuropsicológicos , Esquizofrenia/complicações
7.
Schizophr Res ; 190: 150-159, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28285028

RESUMO

AIM: This longitudinal study aimed to evaluate social cognition of patients with schizophrenia at two points, i.e., during the symptomatic phase and clinical remission phase. Additional aim was to evaluate the relationship of social cognition with psychopathology and functional outcome. METHODOLOGY: Fifty-one patients (N=51) were evaluated on Social Cognition Rating Tools in Indian Setting (SOCRATIS), Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Socio-occupational functioning scale (SOFS) and Indian Disability Evaluation and Assessment Scale (IDEAS) during the symptomatic phase of illness. These patients were followed-up longitudinally for achieving clinical remission. Out of the 51 patients, 32 patients underwent second assessment after a mean duration of 143 (SD 34.9) days, while in clinical remission. Data of 111 healthy controls was used for comparison. RESULTS: Social cognitive deficits were present in both the phases of illness. However, when the baseline and follow-up data was compared, it was evident that the severity of social cognition deficits is lower during the clinical remission phase. Higher levels of social cognitive deficits in both phases of illness are associated with higher socio-occupational dysfunction and higher disability. CONCLUSION: Present study suggests that impairment in social cognition in patients with schizophrenia is present both in symptomatic and remission phase, with higher level of deficits during the symptomatic phase. Social cognition impairments are associated with poor social and occupational functioning and higher level of disability.


Assuntos
Cognição , Esquizofrenia/terapia , Psicologia do Esquizofrênico , Percepção Social , Adolescente , Adulto , Avaliação da Deficiência , Progressão da Doença , Feminino , Seguimentos , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Indução de Remissão , Índice de Gravidade de Doença , Fatores Socioeconômicos , Adulto Jovem
8.
Indian J Pharmacol ; 46(6): 660-1, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25538344

RESUMO

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used for the management of depression and anxiety disorders. The drug has been rarely reported to be associated with the development of akathisia. A review of the literature revealed only three such case reports. In this report we present the case of a middle-aged female, who developed akathisia while receiving venlafaxine (225 mg/day). The patient was suffering from recurrent depressive disorder and Crohn's disease. She was earlier treated with Cap venlafaxine up to 75 mg/day, but had a relapse of depressive symptoms when an attempt was made to taper off venlafaxine. When she presented to us, her depressive symptoms amounted to severe depression without psychotic symptoms. In view of the past response to venlafaxine, she was restarted on venlafaxine, but did not achieve remission of symptoms with the earlier dose and hence, venlafaxine was increased up to 225 mg/day. Within 48 h of increasing venlafaxine to 225 mg/day, she developed akathisia, which subsided after stopping venlafaxine.


Assuntos
Acatisia Induzida por Medicamentos/etiologia , Antidepressivos de Segunda Geração/efeitos adversos , Cicloexanóis/efeitos adversos , Adulto , Antidepressivos de Segunda Geração/uso terapêutico , Cicloexanóis/uso terapêutico , Depressão/tratamento farmacológico , Feminino , Humanos , Cloridrato de Venlafaxina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA